Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
PREMPRO/PREMPHASE is an oral combination hormone replacement therapy (HRT) containing conjugated estrogens and medroxyprogesterone acetate, designed to alleviate vasomotor symptoms and prevent osteoporosis in postmenopausal women. The estrogen component addresses hot flashes and night sweats, while the progestin protects the endometrium. This fixed-dose combination was approved in 2003 as a convenient once-daily alternative to separate hormone therapies.
With LOE approaching and moderate competitive pressure (30%), brand teams should expect resource consolidation and a shift toward lifecycle extension or transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PREMPRO/PREMPHASE offers limited career growth potential given the LOE approaching status and minimal linked job activity. This role is best suited for professionals seeking to manage legacy brands, develop cost-containment strategies, or transition to more innovative pipeline products.
Worked on PREMPRO/PREMPHASE at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.